News

Newsletter

The Term of Patents in Brazil: what a difference a day makes!

Changes in the preliminary injunction granted by the Brazilian Supreme Court
 
As per our Newsletter No. 7/2021, on April 7th, 2021, the Brazilian Supreme Court initiated the judgement of the lawsuit which discuss the term of patents validity in Brazil, namely the Direct Plea of Unconstitutionality No. 5529 (‘DPU’). The DPU Reporting Justice, Mr. Dias Toffoli, considered appropriate to advance his opinion on the merits of the DPU, by granting a preliminary injunction.
 
Remarkably, after one day from the grant of the preliminary injunction, Justice Toffoli rendered a new decision substantially changing the scope of the injunction, aiming “the clarification of the concrete impacts of the decision”. Apparently, there was an error in the previous decision (that made reference to “patents” – which is understood as already issued patents –, and the new decision now expressly makes reference to patent applications).
 
Thus, according to the (new) decision rendered on April 8th, 2021, the Brazilian Patent and Trademark Office (‘BPTO’), shall not henceforth grant any patent with a term beyond 20 years from filing to patents related to “pharmaceutical products and processes and equipment/material used for health services”. This judicial seal, according to the new decision, is limited to pending applications, and issued patents currently still in force are not affected.
 
Mr Toffoli also advanced his personal understanding that the effects of the final decision (to be rendered in the near future by the 11 Justices of the full Court) should retroactively cancel all issued patents that are currently enjoying a term of protection longer than 20 years from filing. We shall eventually know if other Justices have the same opinion.
 
The previous decision (of April 7) has now been substituted by this new one (of April 8), that is immediately applicable, and might be revoked, confirmed or modified by the full Court.
 
In the meantime, as usual, we remain at your disposal for any further clarification, which can be addressed through your usual contact in our office or via e-mail to mail@kasznarleonardos.com.
Back

Last related news

September 6, 2022

Brazilian National Health Surveillance Agency authorizes exceptional drug and vaccine use against Monkeypox by the Ministry of Health

The Ministry of Health (MH) sent Brazilian National Health Surveillance Agency (Anvisa) a request for exemption from the sanitary registration, on an Brazilian National Health Surveillance Agency authorizes exceptional drug and vaccine use against Monkeypox by the Ministry of Health

Ler notícia

August 16, 2022

Brazilian National Health Surveillance Agency (ANVISA) decides to ban Carbendazim

On August 8th, 2022, during the 12th Extraordinary Public Meeting of DICOL, ANVISA’s Collegiate Board of Directors announced the completion of the toxicological Brazilian National Health Surveillance Agency (ANVISA) decides to ban Carbendazim

Ler notícia

July 19, 2022

Carbendazim toxicological revaluation about to be completed by ANVISA

In December 2019, ANVISA started the process of toxicological revaluation of the Active Ingredient (AI) Carbendazim, as signs of toxicity were identified Carbendazim toxicological revaluation about to be completed by ANVISA

Ler notícia